Profile
Elmar Schärli is currently the Director at Zilentin AG and the Chief Financial Officer at Xigen SA. Previously, he worked as the Chief Financial Officer at Altamira Therapeutics Ltd.
from 2019 to 2021.
Elmar Schärli active positions
| Companies | Position | Start |
|---|---|---|
Xigen SA
 Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | Director of Finance/CFO | - |
Zilentin AG
 Zilentin AG Pharmaceuticals: MajorHealth Technology Zilentin AG develops projects for the treatment of tinnitus and hearing loss. The company is headquartered in Zug, Switzerland. | Director/Board Member | - |
Former positions of Elmar Schärli
| Companies | Position | End |
|---|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Director of Finance/CFO | 2021-10-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ALTAMIRA THERAPEUTICS LTD. | Health Technology |
| Private companies | 2 |
|---|---|
Xigen SA
Xigen SA Pharmaceuticals: MajorHealth Technology Xigen SA develops intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer. It focuses on the acute or short-term treatment of major debilitating pathologies that underly unmet medical needs plaguing humanity. The company was founded in 2002 and is headquartered in Epalinges, Switzerland. | Health Technology |
Zilentin AG
Zilentin AG Pharmaceuticals: MajorHealth Technology Zilentin AG develops projects for the treatment of tinnitus and hearing loss. The company is headquartered in Zug, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Elmar Schärli
